ULVR

4,505.5

-1.41%↓

DGE

1,360.5

-1.34%↓

ADM

3,116

-1.7%↓

ULVR

4,505.5

-1.41%↓

DGE

1,360.5

-1.34%↓

ADM

3,116

-1.7%↓

ULVR

4,505.5

-1.41%↓

DGE

1,360.5

-1.34%↓

ADM

3,116

-1.7%↓

ULVR

4,505.5

-1.41%↓

DGE

1,360.5

-1.34%↓

ADM

3,116

-1.7%↓

ULVR

4,505.5

-1.41%↓

DGE

1,360.5

-1.34%↓

ADM

3,116

-1.7%↓

Search

Tate & Lyle PLC

Aperta

SettoreConsumatore difensivo

333 -0.66

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

325.4

Massimo

337

Metriche Chiave

By Trading Economics

Entrata

78M

56M

Vendite

63M

1B

P/E

Media del settore

50.4

28.772

EPS

0.2

Rendimento da dividendi

5.62

Margine di Profitto

5.469

Dipendenti

5,000

EBITDA

95M

188M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+31.39% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

5.62%

3.67%

Utili prossimi

21 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-64M

1.6B

Apertura precedente

333.66

Chiusura precedente

333

Notizie sul Sentiment di mercato

By Acuity

50%

50%

53 / 131 Classifica in Consumer defensive

Tate & Lyle PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 mar 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Discorsi di Mercato

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Discorsi di Mercato

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Principali Notizie su Eventi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato
Utili
Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Tate & Lyle PLC Previsione

Obiettivo di Prezzo

By TipRanks

31.39% in crescita

Previsioni per 12 mesi

Media 433.33 GBX  31.39%

Alto 500 GBX

Basso 390 GBX

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Tate & Lyle PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

1

Acquista

2

Mantieni

0

Vendi

Sentiment

By Acuity

53 / 131 Classifica in Consumatore difensivo

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Tate & Lyle PLC

Tate & Lyle plc, together with its subsidiaries, engages in the provision of ingredients and solutions to the food, beverage, and other industries in North America, Asia, Middle East, Africa, Latin America, and Europe. The company operates through three segments: Food & Beverage Solutions, Sucralose, Primary Products Europe, and Primient. It offers dairy products, soups, sauces, and dressings; bakery products and snacks; texturants; sweeteners, such as high fructose corn syrup and dextrose; industrial starches; acidulants; and corn gluten feed and meal and corn oil. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.
help-icon Live chat